Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase

Medicine & Life Sciences

• Leukemia, Myeloid, Chronic Phase 100%
• Imatinib Mesylate 83%
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive 23%
• 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 21%
• Dasatinib 20%
• Cytogenetics 14%
• Therapeutics 11%
• Hematologic Diseases 8%
• Standard of Care 7%
• Protein-Tyrosine Kinases 6%
• Phosphotransferases 5%
• Physicians 4%
• Recurrence 4%
• Mutation 4%